PMAM
SRPT icon

Picton Mahoney Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Picton Mahoney Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,260
Closed -$2.58M – 501
2023
Q3 		$2.58M Buy
+21,260
New +$2.4M 0.08% 187

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Picton Mahoney Asset Management's SRPT Position: Q4 2023 in Review

Picton Mahoney Asset Management sold out of Sarepta Therapeutics (SRPT) in Q4 2023, closing a stake of 21,260 shares — an estimated $2.58M sold.

Picton Mahoney Asset Management first reported a position in SRPT in Q3 2023 and held it in 1 quarter. The position peaked at $2.58M in Q3 2023. 396 funds tracked by Wall St. Rank hold SRPT as of Q4 2023.

  • Picton Mahoney Asset Management reported no remaining Sarepta Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 21,260 Sarepta Therapeutics shares in Q4 2023, an estimated $2.58M.
  • Picton Mahoney Asset Management first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Sarepta Therapeutics position peaked at $2.58M in Q3 2023.
  • 396 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2023.

Based on Picton Mahoney Asset Management's 13F filing for Q4 2023, filed 6 Feb 2024.